Annual report
4361.TEDINET S100V9D5
Period2023-12-01 → 2024-11-30
Filed2025-02-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.9bn | 2023-12-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥8.6bn | 2022-12-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2021-12-01 → 2022-11-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.9bn | 2020-12-01 → 2021-11-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.6bn | 2019-12-01 → 2020-11-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥378m | 2023-12-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | ¥354m | 2022-12-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥390m | 2023-12-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥345m | 2022-12-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥303m | 2021-12-01 → 2022-11-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥386m | 2020-12-01 → 2021-11-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥83m | 2019-12-01 → 2020-11-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥433m | 2023-12-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥342m | 2022-12-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥336m | 2023-12-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥256m | 2022-12-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2021-12-01 → 2022-11-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥281m | 2020-12-01 → 2021-11-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥59m | 2019-12-01 → 2020-11-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥336m | 2023-12-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | ¥256m | 2022-12-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥8.5bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2022-11-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.9bn | at 2021-11-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.2bn | at 2020-11-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.6bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2023-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.9bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.6bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2022-11-30d | Cons. | Net assets |
| Net assets / equity | ¥2.3bn | at 2021-11-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.0bn | at 2020-11-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥745m | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥745m | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥911m | at 2022-11-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2021-11-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥883m | at 2020-11-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥143m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥470m | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥21m | 2021-12-01 → 2022-11-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥785m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥654m | 2019-12-01 → 2020-11-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥305m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥370m | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥243m | 2021-12-01 → 2022-11-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥246m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥392m | 2019-12-01 → 2020-11-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥139m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥21m | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥162m | 2021-12-01 → 2022-11-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥119m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥222m | 2019-12-01 → 2020-11-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥276.22 | 2023-12-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.88 | 2022-12-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.75 | 2021-12-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥230.99 | 2020-12-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.73 | 2019-12-01 → 2020-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,367.69 | at 2024-11-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,167.14 | at 2023-11-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,980.62 | at 2022-11-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,850.07 | at 2021-11-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,619.73 | at 2020-11-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.8% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.0% | at 2022-11-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2021-11-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.4% | at 2020-11-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.2% | 2023-12-01 → 2024-11-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2022-12-01 → 2023-11-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2021-12-01 → 2022-11-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2020-12-01 → 2021-11-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2019-12-01 → 2020-11-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 171 | at 2024-11-30 | Cons. | Number of employees |
| Employees | 166 | at 2023-11-30 | Cons. | Number of employees |
| Employees | 171 | at 2022-11-30d | Cons. | Number of employees |
| Employees | 165 | at 2021-11-30d | Cons. | Number of employees |
| Employees | 173 | at 2020-11-30d | Cons. | Number of employees |
| Revenue | ¥8.7bn | 2023-12-01 → 2024-11-30 | Standalone | Net sales |
| Revenue | ¥8.4bn | 2022-12-01 → 2023-11-30 | Standalone | Net sales |
| Revenue | ¥8.2bn | 2021-12-01 → 2022-11-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.7bn | 2020-12-01 → 2021-11-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.5bn | 2019-12-01 → 2020-11-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥362m | 2023-12-01 → 2024-11-30 | Standalone | Operating income |
| Operating income | ¥341m | 2022-12-01 → 2023-11-30 | Standalone | Operating income |
| Ordinary income | ¥376m | 2023-12-01 → 2024-11-30 | Standalone | Ordinary income |
| Ordinary income | ¥333m | 2022-12-01 → 2023-11-30 | Standalone | Ordinary income |
| Ordinary income | ¥262m | 2021-12-01 → 2022-11-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥329m | 2020-12-01 → 2021-11-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥59m | 2019-12-01 → 2020-11-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥418m | 2023-12-01 → 2024-11-30 | Standalone | Income before income taxes |
| Profit before tax | ¥330m | 2022-12-01 → 2023-11-30 | Standalone | Income before income taxes |
| Net income | ¥324m | 2023-12-01 → 2024-11-30 | Standalone | Profit loss |
| Net income | ¥246m | 2022-12-01 → 2023-11-30 | Standalone | Profit loss |
| Net income | ¥185m | 2021-12-01 → 2022-11-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥242m | 2020-12-01 → 2021-11-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥40m | 2019-12-01 → 2020-11-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.3bn | at 2024-11-30 | Standalone | Assets |
| Total assets | ¥8.1bn | at 2023-11-30 | Standalone | Assets |
| Total assets | ¥8.2bn | at 2022-11-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.8bn | at 2021-11-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.1bn | at 2020-11-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥5.6bn | at 2024-11-30 | Standalone | Liabilities |
| Total liabilities | ¥5.7bn | at 2023-11-30 | Standalone | Liabilities |
| Net assets / equity | ¥2.7bn | at 2024-11-30 | Standalone | Net assets |
| Net assets / equity | ¥2.5bn | at 2023-11-30 | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2022-11-30d | Standalone | Net assets |
| Net assets / equity | ¥2.1bn | at 2021-11-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.9bn | at 2020-11-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥506m | at 2024-11-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥834m | at 2023-11-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥265.81 | 2023-12-01 → 2024-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.87 | 2022-12-01 → 2023-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.85 | 2021-12-01 → 2022-11-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥198.64 | 2020-12-01 → 2021-11-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.47 | 2019-12-01 → 2020-11-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥60 | 2023-12-01 → 2024-11-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2022-12-01 → 2023-11-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-12-01 → 2022-11-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-12-01 → 2021-11-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2019-12-01 → 2020-11-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,203.77 | at 2024-11-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,015.67 | at 2023-11-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,847.66 | at 2022-11-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,758.24 | at 2021-11-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,573.45 | at 2020-11-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 32.2% | at 2024-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2023-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2022-11-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2021-11-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.9% | at 2020-11-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.6% | 2023-12-01 → 2024-11-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2022-12-01 → 2023-11-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2021-12-01 → 2022-11-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.9% | 2020-12-01 → 2021-11-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2019-12-01 → 2020-11-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,220,000 | at 2024-11-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2023-11-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2022-11-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2021-11-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2020-11-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 165 | at 2024-11-30 | Standalone | Number of employees |
| Employees | 160 | at 2023-11-30 | Standalone | Number of employees |
| Employees | 166 | at 2022-11-30d | Standalone | Number of employees |
| Employees | 159 | at 2021-11-30d | Standalone | Number of employees |
| Employees | 167 | at 2020-11-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | capex | 2023-12-01 → 2024-11-30 | ¥344m |
| Pharmaceutical Productsreportable segment | depreciation | 2023-12-01 → 2024-11-30 | ¥404m |
| Pharmaceutical Productsreportable segment | employees | at 2024-11-30 | 170 pure |
| Pharmaceutical Productsreportable segment | revenue | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Pharmaceutical Productsreportable segment | revenue external | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Pharmaceutical Productsreportable segment | segment assets | at 2024-11-30 | ¥8.5bn |
| Pharmaceutical Productsreportable segment | segment profit | 2023-12-01 → 2024-11-30 | ¥347m |
| Real Estate Leasingreportable segment | employees | at 2024-11-30 | 1 pure |
| Real Estate Leasingreportable segment | revenue | 2023-12-01 → 2024-11-30 | ¥38m |
| Real Estate Leasingreportable segment | revenue external | 2023-12-01 → 2024-11-30 | ¥38m |
| Real Estate Leasingreportable segment | segment assets | at 2024-11-30 | ¥71m |
| Real Estate Leasingreportable segment | segment profit | 2023-12-01 → 2024-11-30 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-12-01 → 2024-11-30 | ¥344m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-12-01 → 2024-11-30 | ¥404m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-11-30 | ¥8.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-12-01 → 2024-11-30 | ¥378m |
| Pharmaceutical Productsreportable segment | capex | 2022-12-01 → 2023-11-30 | ¥314m |
| Pharmaceutical Productsreportable segment | depreciation | 2022-12-01 → 2023-11-30 | ¥406m |
| Pharmaceutical Productsreportable segment | revenue | 2022-12-01 → 2023-11-30 | ¥8.6bn |
| Pharmaceutical Productsreportable segment | revenue external | 2022-12-01 → 2023-11-30 | ¥8.6bn |
| Pharmaceutical Productsreportable segment | segment assets | at 2023-11-30 | ¥8.3bn |
| Pharmaceutical Productsreportable segment | segment profit | 2022-12-01 → 2023-11-30 | ¥323m |
| Real Estate Leasingreportable segment | revenue | 2022-12-01 → 2023-11-30 | ¥38m |
| Real Estate Leasingreportable segment | revenue external | 2022-12-01 → 2023-11-30 | ¥38m |
| Real Estate Leasingreportable segment | segment assets | at 2023-11-30 | ¥71m |
| Real Estate Leasingreportable segment | segment profit | 2022-12-01 → 2023-11-30 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-12-01 → 2023-11-30 | ¥314m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-12-01 → 2023-11-30 | ¥406m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-11-30 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-11-30 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-11-30 | ¥8.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-11-30 | ¥354m |
| Pharmaceutical Productsreportable segment | employees | at 2024-11-30 | 164 pure |
| Real Estate Leasingreportable segment | employees | at 2024-11-30 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,493
| Item | Context | Value | Unit |
|---|---|---|---|
| Shipping expenses and storage fee selling expenses | CurrentYearDuration | 221793000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YearDuration | 386000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration | 483000 | JPY |
| Directors compensations sga | Prior1YearDuration | 73873000 | JPY |
| Directors compensations sga | CurrentYearDuration | 77082000 | JPY |
| Employee payrolls and allowances general and administrative expenses | Prior1YearDuration | 364648000 | JPY |
| Employee payrolls and allowances general and administrative expenses | CurrentYearDuration | 375670000 | JPY |
| Legal welfare expenses sga | Prior1YearDuration | 26723000 | JPY |
| Legal welfare expenses sga | CurrentYearDuration | 28030000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 240396000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 259169000 | JPY |
| Depreciation research and development expenses | Prior1YearDuration | 65898000 | JPY |
| Depreciation research and development expenses | CurrentYearDuration | 61185000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 31791000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 37371000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration | 16200000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration | 17100000 | JPY |
| Provision for directors retirement benefits sga | Prior1YearDuration | 8985000 | JPY |
| Provision for directors retirement benefits sga | CurrentYearDuration | 8906000 | JPY |
| Depreciation sga | Prior1YearDuration | 15800000 | JPY |
| Depreciation sga | CurrentYearDuration | 13254000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 240396000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 259169000 | JPY |
| Write downs of inventories | Prior1YearDuration | -23025000 | JPY |
| Write downs of inventories | CurrentYearDuration | 32225000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 8572121000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01006-000RealEstateLeasingReportableSegmentMember | 38274000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 8610396000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 8610396000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 8572121000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01006-000RealEstateLeasingReportableSegmentMember | 38274000 | JPY |
| Net sales | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 8610396000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YearDuration | 8610396000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 323248000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E01006-000RealEstateLeasingReportableSegmentMember | 30666000 | JPY |
| Operating income | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 353914000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YearDuration | 353914000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 8269568000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E01006-000RealEstateLeasingReportableSegmentMember | 71026000 | JPY |
| Assets | Prior1YearInstant_TotalOfReportableSegmentsAndOthersMember | 8340594000 | JPY |
| Assets | Prior1YearInstant_ReconcilingItemsMember | － | JPY |
| Assets | Prior1YearInstant | 8340594000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |